Our non-clinical activities yielded promising results in influenza and COVID-19 cell line studies and animal studies. We’re now planning the Phase 2 “SURVIVE” trial to explore zapnometinib’s efficacy as the first treatment for patients hospitalized with severe influenza. Visit our poster presentation at ESWI (https://eswiconference.org/) and learn more about Atriva and zapnometinib. For further information, you can also contact us at info@atriva-therapeutics.com.